Trial Profile
Prospective, multi-center, randomized, double-blind, two-arm, parallel group, active control, comparative clinical study to evaluate efficacy and safety of R-TPR-024 / Lucentis in patients with neovascular (wet) age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2020
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Sponsors Reliance Life Sciences
- 30 Jun 2020 Status changed from active, no longer recruiting to completed.
- 05 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Nov 2018 New trial record